-
公开(公告)号:US20130338092A1
公开(公告)日:2013-12-19
申请号:US13969213
申请日:2013-08-16
申请人: The Broad Institute, Inc. , The General Hospital Corporation , Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , President and Fellows of Harvard College , Sloan-Kettering Institute for Cancer Research
发明人: Kimberly Hartwell , Malcolm A.S. Moore , David T. Scadden , Stuart L. Schreiber , Todd R. Golub , Benito Munoz , Benjamin L. Ebert , Andrew M. Stern , Peter G. Miller , D. Gary Gilliland , Anne Van Dyk Carpenter , David J. Logan , Joseph Negri , Nicola Tolliday , Alykhan Shamji , Siddhartha Mukherjee , Alison Stewart
IPC分类号: G01N33/50 , A61K31/4184 , A61K31/395 , A61K31/428 , A61K31/423 , A61K31/704 , A61K31/4745 , A61K31/405 , A61K31/4418 , A61K31/366 , A61K31/22 , A61K31/167 , A61K31/444
CPC分类号: G01N33/5011 , A61K31/167 , A61K31/22 , A61K31/366 , A61K31/395 , A61K31/405 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4418 , A61K31/444 , A61K31/4745 , A61K31/704 , A61K45/06
摘要: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.
摘要翻译: 本发明涉及用于鉴定有效靶向白血病干细胞的化合物的高通量半自动化方法,以及通过这些方法鉴定的化合物及其用于治疗白血病的用途。
-
公开(公告)号:US10724099B2
公开(公告)日:2020-07-28
申请号:US14385545
申请日:2013-03-14
发明人: Channing Yu , Todd R. Golub
IPC分类号: C12P19/34 , C12Q1/6886 , G01N33/50 , C12Q1/686
摘要: Methods to simultaneously test and screen multiplexed, mixed cell populations, e.g., populations comprising genetically heterogeneous cancer cells, in common conditions.
-
公开(公告)号:US20150044676A1
公开(公告)日:2015-02-12
申请号:US14385545
申请日:2013-03-14
发明人: Channing Yu , Todd R. Golub
IPC分类号: C12Q1/68
摘要: Methods to simultaneously test and screen multiplexed, mixed cell populations, e.g., populations comprising genetically heterogeneous cancer cells, in common conditions.
摘要翻译: 在常见的条件下同时测试和筛选多重混合细胞群体,例如包含遗传异质性癌细胞的种群的方法。
-
公开(公告)号:US11111296B2
公开(公告)日:2021-09-07
申请号:US16061652
申请日:2016-12-13
发明人: David K. Thomas , Todd R. Golub
IPC分类号: G01N33/48 , G01N31/00 , C07K16/28 , G16C20/00 , G16C10/00 , G16C20/64 , G16C20/50 , G16C20/20 , G16C20/62 , G16C20/60 , A61P9/10 , A61P9/04 , A61K39/00 , A61K38/17
摘要: The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.
-
公开(公告)号:US11058903B2
公开(公告)日:2021-07-13
申请号:US16229176
申请日:2018-12-21
发明人: David K. Thomas , Todd R. Golub
IPC分类号: A61P21/06 , A61K39/395 , A61K38/17 , A61K38/04 , C07K16/28 , A61K31/05 , A61K31/164 , A61K31/454 , A61K31/506 , A61K31/519 , A61K31/7068 , A61K38/00 , C07K14/705 , C07K7/08 , G01N33/53 , A61P3/00 , G01N33/68 , G01N33/50 , A61K45/06 , A61K39/00
摘要: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
-
公开(公告)号:US20210169827A1
公开(公告)日:2021-06-10
申请号:US17161431
申请日:2021-01-28
申请人: THE BROAD INSTITUTE, INC. , THE BRIGHAM & WOMEN'S HOSPITAL, INC. , DANA-FARBER CANCER INSTITUTE, INC. , Instituto Carlos Slim de la Salud, A.C.
发明人: Anna Greka , Moran Dvela-Levitt , Maria Alimova , Eric Lander , Todd R. Golub , Florence Wagner , Brian Chamberlain , Valeria Padovano , Joseph Growney
IPC分类号: A61K31/13 , A61P13/12 , A61P27/02 , C12Q1/6883
摘要: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
-
公开(公告)号:US10191033B2
公开(公告)日:2019-01-29
申请号:US15101865
申请日:2014-12-04
发明人: David K. Thomas , Todd R. Golub
IPC分类号: G01N33/53 , A61P3/00 , G01N33/50 , G01N33/68 , A61K31/519 , A61K31/7068 , A61K39/395 , A61K38/00 , A61K39/00
摘要: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
-
公开(公告)号:US20230115675A1
公开(公告)日:2023-04-13
申请号:US17905013
申请日:2021-02-26
发明人: Todd R. Golub , Peter Tsvetkov
IPC分类号: A61K31/325 , G01N33/50 , A61P35/00
摘要: Provided herein are methods and compositions related to the treatment of cancer using copper ionophores.
-
公开(公告)号:US20230075965A1
公开(公告)日:2023-03-09
申请号:US17793581
申请日:2021-01-22
申请人: Constantine S. Mitsiades , Michal Sheffer , Jennifer Roth , Chris C. Mader , Channing Yu , Todd R. Golub , Lotte Wieten , Dana-Farber Cancer Institute, Inc. , The Broad Institute, Inc. , Maastricht University Medical Center
发明人: Constantine S. Mitsiades , Michal Sheffer , Jennifer Roth , Chris C. Mader , Channing Yu , Todd R. Golub , Lotte Wieten
IPC分类号: G01N33/574 , A61K35/17 , A61P35/00 , A61P37/04 , C12N15/10 , A61K31/713 , A61K31/4045 , A61K45/06
摘要: The present invention relates, in part, to methods for selecting subjects for and treating subjects with a type of immunotherapy based on certain biomarkers from the subjects.
-
公开(公告)号:US20220023233A1
公开(公告)日:2022-01-27
申请号:US17494830
申请日:2021-10-06
申请人: THE BROAD INSTITUTE, INC. , THE BRIGHAM & WOMEN'S HOSPITAL, INC. , DANA-FARBER CANCER INSTITUTE, INC. , Instituto Carlos Slim de la Salud, A.C.
发明人: Anna Greka , Moran Dvela-Levitt , Maria Alimova , Eric Lander , Todd R. Golub , Florence Wagner , Brian Chamberlain , Valeria Padovano , Joseph Growney
IPC分类号: A61K31/13 , A61P27/02 , A61P13/12 , C12Q1/6883
摘要: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
-
-
-
-
-
-
-
-
-